Sep 09, 2015 - Benchmarks ended higher on Tuesday after weak Chinese trade data raised hopes that further stimulus measures will be announced to boost its fragile economy
Sep 03, 2015 - Novartis (NVS) launched Zarxio (biosimilar version of Amgen's Neupogen) in the U.S., which became the first FDA-approved biosimilar to be launched in the country.
Sep 03, 2015 - The Zacks Analyst Blog Highlights: Amgen, ARIAD, Celgene, Amicus and Alnylam
Sep 02, 2015 - Amgen (AMGN) inks deal with Novartis for Alzheimer's disease and migraine; reports positive phase III data on romosozumab.
Sep 02, 2015 - Regeneron Pharmaceuticals, Inc. (REGN) and its partner Sanofi (SNY) presented encouraging data from a phase III study on their Praluent, at the ESC Congress 2015.
Sep 02, 2015 - AstraZeneca (AZN) strikes a collaboration agreement with Valeant for the development and commercialization of brodalumab.
Sep 02, 2015 - ARIAD's (ARIA) shares shot up on acquisition rumors; Amgen (AMGN) gained FDA approval for its potential blockbuster treatment, Repatha.
Aug 31, 2015 - Alnylam (ALNY) and The Medicines Company (MDCO) presented initial data from their ongoing phase I study on ALN-PCSsc for the treatment of hypercholesterolemia.
Aug 28, 2015 - Will FDA approval of Amgen's (AMGN) Repatha trigger a pricing war for this class of treatment?
Aug 27, 2015 - The Zacks Analyst Blog Highlights: Vital Therapies, Amgen, BioMarin, Acorda and Macrocure